骨肉瘤的新辅助化疗

New Adjuvant Chemotherapy for Osteosarcoma

目的:对36例采用新辅助化疗的骨肉瘤患者进行回顾性分析。方法:36例骨肉瘤患者均采用新辅助化疗。第1周期AP方案:用法ADM60mg/m2、DDP120mg/m2;第2、3周期大剂量MTX方案:MTX200mg/kg或8g/m2(成人),12g/m2(儿童);第4周期IFO方案:IFO2g/m2,连用5天,每一周期间隔10～15天,4个周期为1疗程;术前化疗2个疗程,术后化疗3～4个疗程。结果:采用新辅助化疗的36例患者中,最终保肢率为(30/36)83.3%,1～3年生存率(36/36)100%,4年生存率(26/36)72.2%,5年生存率(20/36)55.6%,随访率100%。结论:新辅助化疗不仅可以提高骨肉瘤患者的生存率,尚可增加保肢手术成功率,提高患者的生存质量。

Objective:Making Retrospective a na lyses of the osteosarcoma patients adopting new adjuvant chemotherapy in36ca ses.Methods:The new adjuvant chemotherapy was adopt-ed on all the osteosarco ma patients in36cases.AP scheme for the first cycle:Therapy:Admin-istere d ADM60mg/m 2 .administered DDP120mg/m 2 .high-dose MTX scheme for the second and third cycles:Administered MTX2 00mg/kg or8g/m 2 (adult)12g/m 2 (children).IFO scheme for the fourth cycle:Administered IFO2g/m 2 for5successive days at an interval of10～15days be-tween each cycle,w ith if cycles as a treatment course.Made chemotherapy for2treatment cours-e s before operation and for3～4treatment courses after operation.Results:Of the patients adopt-ing the new adjuvant chemotherapy in36cases,the final e xtremity-keeping cate was(30/36)83.33%,1～3year survival rate w as(36/36)100%,4year survival rate was(26/36)72.22%,5 year survival rate was(20/36)55.56%,and randomized visit rate was 100%.Conclusion:The new adjuvant chemotherapy adopted on the osteosarcoma patients of36cases had marked curative effect.The new adjuvant chemotherap y can not only improve the existing strength of osteosarcoma patients,but als o increase the success rate of extremity-keeping operation and enhance the exis t-ing quality of patients.